Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4595-4605

  Pastorino, Fabio ^a   Brignole, Chiara ^a   Marimpietri, Danilo ^a   Pagnan, Gabriella ^a   Morando, Adriana ^a   Ribatti, Domenico ^b   Semple, Sean C ^c   Gambini, Claudio ^a   Allen, Theresa M ^d   Ponzoni, Mirco ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Inex Pharmaceuticals   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; GANGLIOSIDE; LIPOSOME; MONOCLONAL ANTIBODY; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DOWN REGULATION; FEMALE; LUNG METASTASIS; MELANOMA; METASTASIS; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT PLANNING; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; GANGLIOSIDES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSOMES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; SKIN NEOPLASMS; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 10744233586     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Balch, M., Houghton, A., and Peters, L. Cutaneous Melanoma. In: V. T. DeVita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer Principles of Oncology, pp. 1499-1542. Philadelphia: Lippincott-Raven, 1989.
2. Marshall, E. Cancer warriors claim a victory. Science (Wash. DC), 279: 1842-1843, 1998.
3. Cole, M. D. The myc oncogene: its role in transformation and differentiation. Annu. Rev. Genet., 20: 361-384, 1986.
4. Dang, C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol., 19: 1-11, 1999.
5. Green, D. R., and Evan, G. I. A matter of life and death. Cancer Cell, 1: 19-30, 2002.
6. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 108: 153-164, 2002.
7. Cory, S., and Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer, 2: 647-656, 2002.
8. Crooke, S. T. Therapeutic applications of oligonucleotides. Annu. Rev. Pharmacol. Toxicol., 32: 329-376, 1993.
9. Monia, B. P., Johnston, F. J., Geiger, T., Muller, M., and Fabbro, D. Antitumor activity of a phosphorotioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med., 2: 668-675, 1996.
10. Neurath, M. F., Pettersson, S., Meyer zum Buchenfelde, K. H., and Strober, W. Local administration of antisense phosphoothioate oligonucleotides to the p65 subunit of NF-kB abrogates established experimental colitis in mice. Nat. Med., 2: 998-1004, 1996.
11. Heere-Ress, E., Thallinger, C., Lucas, T., Schlagbauer-Wadl, H., Wacheck, V., Monia, B. P., Wolff, K., Pehamberger, H., and Jansen, B. Bc1-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int. J. Cancer, 99: 29-34, 2002.
12. Eberle, J., Fecker, L. F., Bittner, J. U., Orfanos, C. E., and Geilen, C. C. Decreased proliferation of human melanoma cell lines caused by antisense RNA against translation factor eLF-4A1. Br. J. Cancer, 86: 1957-1962, 2002.
13. Skorski, T., Perrotti, D., Nieborowska-Skorski, M., Gryaznov, S., and Calabretta, B. Antileukemia effect of c-myc N3′-P5′ phosphoramidate antisense oligonucleotides in vivo. Proc. Natl. Acad. Sci. USA, 94: 3966-3971, 1997.
14. Citro, G., D'Agnano, I., Leonetti, C., Perini, R., Bucci, B., Zon, G., Calabretta, B., and Zupi, G. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res., 58: 283-289, 1998.
15. Leonetti, C., D'Agnano, I., Lozupone, F., Valentini, A., Geiser, T., Zon, G., Calabretta, B., Citro, G., and Zupi, G. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J. Natl. Cancer Inst., 88: 419-429, 1996.
16. Wagner, R. W. The state of the art in antisense research. Nat. Med., 1: 1116-1118, 1995.
17. Wang, S., Lee, R. J., Cauchon, G., Gorestein, D. G., and Low, P. S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA, 92: 3318-3322, 1995.
18. Zelphati, O., and Szoka, F. C. J. Liposomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet? J. Control. Rel., 41: 99-119, 1996.
19. Gokhale, P. C., Soldatenkov, V., Wang, F. H., Rahman, A., Dritschilo, A., and Kasid, U. Antisense raf oligodeoxynucleotide is protected by liposomal encapsulation and inhibits Raf-1 protein expression in vitro and in vivo: implications for gene therapy of radioresistant cancer. Gene Ther., 4: 1289-1299, 1997.
20. Guterriez-Puente, Y., Tari, A. M., Stephens, C., Rosenblum, M., Guerra, R. T., and Lopez-Berestein, G. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. Pharmacol. Exp. Ther., 291: 865-869, 1999.
21. Stuart, D. D., Kao, G. Y., and Allen, T. M. A novel, long-circulating, and functional liposomal formulation of antisense oligodeoxynucleotides targeted against MDR1. Cancer Gene Ther., 7: 466-475, 2000.
22. Leonetti, C., Biroccio, A., Benassi, B., Stringaro, A., Stoppacciaro, A., Semple, S. C., and Zupi, G. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther., 8: 459-468, 2001.
23. Allen, T. M., and Moase, E. H. Therapeutic opportunities for targeted liposomal drug delivery. Adv. Drug Del. Rev., 21: 117-133, 1996.
24. Pagnan, G., Montaldo, P. G., Pastorino, F., Raffaghello, L., Kirchmeier, M., and Allen, T. M. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J. Cancer, 81: 268-274, 1999.
25. Pastorino, F., Brignole, C., Marimpietri, D., Sapra, P., Moase, E. H., Allen, T. M., and Ponzoni, M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res., 63: 86-92, 2003.
26. Raffaghello, L., Pagnan, G., Pastorino, F., Cosimo, E., Brignole, C., Marimpietri, D., Montaldo, P. G., Gambini, C., Allen, T. M., Bogenmann, E., and Ponzoni, M. In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma. Int. J. Cancer. 104: 559-567, 2003.
27. Schulz, G., Cheresh, D. A., Vark, N. M., Yu, A., Staffileno, L. K., and Reisfeld, R. A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res., 44: 5914-5920, 1984.
28. Pagnan, G., Stuart, D. D., Pastorino, F., Raffaghello, L., Montaldo, P. G., Allen, T. M., Calabretta, B., and Ponzoni, M. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD2-targeted immunoliposomes: antitumor effects. J. Natl. Cancer Inst., 92: 253-261, 2000.
29. Stuart, D. D., and Allen, T. M. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta, 1463: 219-229, 2000.
30. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W. L., Carter, P., Benz, C. C., and Papahadjopoulos, D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36: 66-75, 1997.
31. Pastorino, F., Stuart, D. D., Ponzoni, M., and Allen, T. M. Targeted delivery of antisense oligonucleotides in cancer. J. Control. Rel., 74: 69-75, 2001.
32. Ribatti, D., Polimeno, G., Vacca, A., Marzullo, A., Crivellato, E., Nico, B., Lucarelli, G., and Dammacco, F. Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. Leukemia (Baltimore), 16: 1680-1684, 2002.
33. Allen, T. M., and Hansen, C. Pharmacokinetics of stealth versus conventional liposomes: effect and dose. Biochim. Biophys. Acta, 1068: 133-141, 1991.
34. Middleton, M. R., Lorigan, P., and Owen, J. A randomized phase III study comparing decarbazine, BCNU, cisplatin and tamoxifen with decarbazine and interferon in advanced melanoma. Br. J. Cancer, 82: 1158-1162, 2000.
35. Stein, C., and Cheng, Y. C. Antisense oligonucleotides as therapeutic agents. Is the bullet really magical? Science (Wash. DC), 261: 1004-1012, 1993.
36. Galderisi, U., Cascino, A., and Giordano, A. Antisense oligonucleotides as therapeutic agents. J. Cell. Physiol., 181: 251-257, 1999.
37. Webb, M. S., Harasym, T. O., Masin, D., Bally, M. B., and Mayer, L. D. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumor models. Br. J. Cancer, 72: 896-904, 1995.
38. Smith, J. B., and Wickstrom, E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. J. Natl. Cancer Inst., 90: 1146-1154, 1998.
39. Tamm, I., Dorken, B., and Hartmann, G. Antisense therapy in oncology: new hope for an old idea?. Lancet, 358: 489-497, 2001.
40. Hersey, P., and Zhang, X. D. How melanoma cells evade trail-induced apoptosis. Nat. Rev. Cancer, 1: 1142-150, 2001.
41. Shi, Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol. Cell, 9: 459-470, 2002.
42. Huwyler, J., Wu, D., and Pardridge, W. M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA. 93: 14164-14169, 1996.
43. Lopez De Menezes, D. E., Pilarski, L. M., and Allen, T. M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res., 58: 3320-3330, 1998.
44. Allen, T. M., Ahmad, I., Lopez De Menezes, D. E., and Moase, E. H. Immunoliposome mediated targeting of anti-cancer drugs in vivo. Biochem. Soc. Trans., 23: 1073-1079, 1995.
45. Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., and Jain, R. K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res., 54: 3352-3356, 1994.
46. McClay, E. F. Adjuvant therapy for patients with high-risk malignant melanoma. Semin. Oncol., 29: 389-399, 2002.
47. Eggermont, A. M., and Gore, M. European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma. Semin. Oncol., 29: 382-388, 2002.
48. DiFronzo, L. A., Gupta, R. K., Essner, R., Foshag, L. J., O'Day, S. J., Wanek, L. A., Stern, S. L., and Morton, D. L. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J. Clin. Oncol., 20: 3242-3248, 2002.